BioNTech, CEPI Partnership To Develop Mpox Vaccine

BioNTech of Germany has announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to further the development of its mpox vaccine. CEPI will provide funding of up to $90 million to support the development of vaccine candidates which is based on BioNTech's mRNA technology, as per reuters. The partnership is part of BioNTech's strategy to develop vaccines for the prevention of high-medical-need infectious diseases, including diseases that disproportionally affect lower-income countries, the company said. BioNTech is a worldwide immunotherapy powerhouse with a fully integrated approach.

We have been working on automated and digitized processes, and we are constantly developing capacities for specialized manufacturing, whether for individualized vaccinations or large-scale products such as our COVID-19 vaccine. We are also constantly assessing long-term strategies for democratizing access to healthcare. CEPI is a innovative global partnership between public, private, philanthropic, and civil society organisations. We're working together to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.